IGC Latest Press Releases

-- December 19, 2025 --

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum ACCESS Newswire 9:00 AM

-- December 15, 2025 --

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines ACCESS Newswire 9:00 AM

-- December 10, 2025 --

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." ACCESS Newswire 9:00 AM

-- December 9, 2025 --

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial ACCESS Newswire 9:00 AM

-- December 2, 2025 --

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease ACCESS Newswire 9:00 AM

-- November 25, 2025 --

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends ACCESS Newswire 9:00 AM

-- November 17, 2025 --

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital ACCESS Newswire 8:30 AM

-- November 13, 2025 --

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders ACCESS Newswire 9:00 AM

-- November 10, 2025 --

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025 ACCESS Newswire 9:00 AM

-- November 3, 2025 --

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline ACCESS Newswire 8:53 AM

-- October 22, 2025 --

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant" ACCESS Newswire 9:00 AM

-- October 14, 2025 --

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences ACCESS Newswire 9:00 AM

-- October 10, 2025 --

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders ACCESS Newswire 7:50 PM

-- October 7, 2025 --

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease ACCESS Newswire 9:00 AM

-- September 29, 2025 --

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial ACCESS Newswire 9:00 AM

-- September 24, 2025 --

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology ACCESS Newswire 9:00 AM

-- September 22, 2025 --

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial ACCESS Newswire 9:00 AM

-- September 9, 2025 --

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection ACCESS Newswire 9:17 AM

-- September 2, 2025 --

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada ACCESS Newswire 9:00 AM

-- August 28, 2025 --

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome ACCESS Newswire 9:00 AM

-- August 27, 2025 --

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50." ACCESS Newswire 9:00 AM

-- August 25, 2025 --

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City ACCESS Newswire 9:00 AM

-- August 19, 2025 --

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial ACCESS Newswire 9:00 AM

-- August 12, 2025 --

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1 ACCESS Newswire 9:00 AM

-- August 5, 2025 --

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression ACCESS Newswire 9:00 AM